BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...who have at least one CF gene mutation that is responsive to Symdeko Company Setback Aradigm Corp....
BioCentury | Apr 6, 2018
Clinical News

Aradigm's Linhaliq under EMA review for lung infection

...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm...
...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm...
...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
BioCentury | Apr 5, 2018
Company News

Aradigm's Linhaliq under EMA review for lung infection

...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm...
...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm...
...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
BioCentury | Feb 14, 2018
Company News

Aradigm execs resign weeks after CRL

...filing. The company named Chairman John Siebert as executive chairman and interim principal executive officer. Aradigm...
...the Company’s cash resources until additional sources of capital can be identified." On Jan. 29, Aradigm...
...from Aradigm under a 2013 deal. On Monday, the first trading day after the resignations, Aradigm...
BioCentury | Feb 2, 2018
Clinical News

Aradigm gets CRL for Linhaliq

...lung infections. The company says it plans to resubmit the NDA “as soon as possible.” Aradigm...
...rights to Linhaliq from Aradigm under a 2013 deal (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
...Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain Product: Linhaliq liposomal ciprofloxacin (ARD-3150) Business: Pulmonary Alicia Parker ARD-3150 Linhaliq Liposomal ciprofloxacin Aradigm Corp. Grifols...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Pharmaceuticals Inc. (NASDAQ:AQXP) Rosiptor Bladder pain syndrome (BPS)/interstitial cystitis Top-line Ph III LEADERSHIP data 3Q18 Aradigm Corp....
...Biosciences Inc. (NASDAQ:APRI) / Allergan plc (NYSE:AGN) Vitaros alprostadil Erectile dysfunction (ED) PDUFA date 2/17/18 Aradigm Corp....
BioCentury | Sep 29, 2017
Clinical News

Aradigm's Linhaliq gets PDUFA date

...rights to Linhaliq from Aradigm under a 2013 deal (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
...Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain Product: Linhaliq liposomal ciprofloxacin (ARD-3150) Business: Pulmonary Alicia Parker ARD-3150 Linhaliq Liposomal ciprofloxacin Aradigm Corp. Grifols...
BioCentury | Sep 25, 2017
Company News

Aradigm's Linhaliq gets PDUFA date

...free ciprofloxacin for inhalation. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm...
...Monday, Grifols gained $0.14 to $21.12 on NASDAQ and €0.32 to €23.86 in Madrid. Alicia Parker ARD-3150 Linhaliq Liposomal ciprofloxacin Aradigm Corp. Grifols...
BioCentury | Feb 16, 2017
Clinical News

Pulmaquin: Ph III ORBIT-3 and ORBIT-4 data

...In December, Aradigm reported mixed data from the identical, 48-week, double-blind, international Phase III ORBIT-3 and...
...endpoint of reducing pulmonary exacerbation frequency vs. placebo in ORBIT-4 (HR=0.63, p=0.0007). In both trials, Aradigm...
...rights to Pulmaquin under a 2013 deal with Aradigm (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
BioCentury | May 2, 2016
Financial News

Aradigm completes private placement of senior convertible notes

Aradigm Corp. (NASDAQ:ARDM), Hayward, Calif. Business: Drug delivery, Pulmonary Date completed: 2016-04-22 Type: Private placement of senior convertible notes Raised: $23 million Shares outstanding prior: 14.8 million Note: The senior notes bear 9% interest, mature...
Items per page:
1 - 10 of 293
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...who have at least one CF gene mutation that is responsive to Symdeko Company Setback Aradigm Corp....
BioCentury | Apr 6, 2018
Clinical News

Aradigm's Linhaliq under EMA review for lung infection

...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm...
...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm...
...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
BioCentury | Apr 5, 2018
Company News

Aradigm's Linhaliq under EMA review for lung infection

...Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm...
...DNA gyrase inhibitor, mixed with a solution of free ciprofloxacin for inhalation. On Jan. 29, Aradigm...
...same indication, prompting the biotech's shares to fall 29% to $1.59 that day. In mid-February, Aradigm's...
BioCentury | Feb 14, 2018
Company News

Aradigm execs resign weeks after CRL

...filing. The company named Chairman John Siebert as executive chairman and interim principal executive officer. Aradigm...
...the Company’s cash resources until additional sources of capital can be identified." On Jan. 29, Aradigm...
...from Aradigm under a 2013 deal. On Monday, the first trading day after the resignations, Aradigm...
BioCentury | Feb 2, 2018
Clinical News

Aradigm gets CRL for Linhaliq

...lung infections. The company says it plans to resubmit the NDA “as soon as possible.” Aradigm...
...rights to Linhaliq from Aradigm under a 2013 deal (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
...Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain Product: Linhaliq liposomal ciprofloxacin (ARD-3150) Business: Pulmonary Alicia Parker ARD-3150 Linhaliq Liposomal ciprofloxacin Aradigm Corp. Grifols...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Pharmaceuticals Inc. (NASDAQ:AQXP) Rosiptor Bladder pain syndrome (BPS)/interstitial cystitis Top-line Ph III LEADERSHIP data 3Q18 Aradigm Corp....
...Biosciences Inc. (NASDAQ:APRI) / Allergan plc (NYSE:AGN) Vitaros alprostadil Erectile dysfunction (ED) PDUFA date 2/17/18 Aradigm Corp....
BioCentury | Sep 29, 2017
Clinical News

Aradigm's Linhaliq gets PDUFA date

...rights to Linhaliq from Aradigm under a 2013 deal (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
...Calif. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), Barcelona, Spain Product: Linhaliq liposomal ciprofloxacin (ARD-3150) Business: Pulmonary Alicia Parker ARD-3150 Linhaliq Liposomal ciprofloxacin Aradigm Corp. Grifols...
BioCentury | Sep 25, 2017
Company News

Aradigm's Linhaliq gets PDUFA date

...free ciprofloxacin for inhalation. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights to Linhaliq from Aradigm...
...Monday, Grifols gained $0.14 to $21.12 on NASDAQ and €0.32 to €23.86 in Madrid. Alicia Parker ARD-3150 Linhaliq Liposomal ciprofloxacin Aradigm Corp. Grifols...
BioCentury | Feb 16, 2017
Clinical News

Pulmaquin: Ph III ORBIT-3 and ORBIT-4 data

...In December, Aradigm reported mixed data from the identical, 48-week, double-blind, international Phase III ORBIT-3 and...
...endpoint of reducing pulmonary exacerbation frequency vs. placebo in ORBIT-4 (HR=0.63, p=0.0007). In both trials, Aradigm...
...rights to Pulmaquin under a 2013 deal with Aradigm (see BioCentury, Sept. 2, 2013 ). Aradigm Corp....
BioCentury | May 2, 2016
Financial News

Aradigm completes private placement of senior convertible notes

Aradigm Corp. (NASDAQ:ARDM), Hayward, Calif. Business: Drug delivery, Pulmonary Date completed: 2016-04-22 Type: Private placement of senior convertible notes Raised: $23 million Shares outstanding prior: 14.8 million Note: The senior notes bear 9% interest, mature...
Items per page:
1 - 10 of 293